Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2000

View Archived Issues

Advanced Tissue Sciences restructures joint venture for Dermagraft during Q4

Lundbeck highlights significant events during 1999

Lilly files NDA for new formulation of Prozac for depression

IND filed by NeoPharm for glioblastoma treatment

Isotechnika receives Canadian approval for human testing of immunosuppressive drug

CytRx to continue Flocor development as treatment for sickle cell disease

Aventis launches new antibiotic in Canada

Anesta renegotiates U.S. marketing rights for Actiq with Abbott

Multiple-dose clinical study of Betabloc as Alzheimer's therapy to begin soon

EGF receptor tyrosine kinase inhibitor selected for clinical testing at Parke-Davis

Otsuka prepares new orally active analgesic agents

Maleimide PKC inhibitors designed by Japan Tobacco

New agents for insulin resistance syndrome in the Merck pipeline

Meiji Seika discloses wide series of carbapenems and orally bioavailable esters

Neurocrine Biosciences' GnRH antagonist program advances

Rhein Biotech aims to become a world leader in vaccines with GCV acquisition

Selective glucocorticoid receptor modulators discovered by Abbott

Ampakine-like compounds for psychiatric and neurological disorders

Antiepileptic agents under study at Arzneimittelwerk Dresden

Potent, selective c-Src TK inhibitor identified using new target-based method

BOM-1006 selected as a lead benzimidazole for the development of antiallergic agents

Schering-Plough to copromote Tequin in U.S.; Tequin evaluated in PROVE IT trial

New use for teprenone in myocardial preconditioning? Evidence presented at ACC meeting

Continued treatment with Enbrel safe and effective in chronic heart failure

Nicostatin effective for increasing "good" cholesterol, lowering "bad" cholesterol

Monsanto and Pharmacia & Upjohn proceed towards completion of merger

Novel features of H-345/52 indicate promising activity in tachyarrhythmia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...